Letter to the Editor
Reply to: Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer
AME Clinical Trials Review
2026;
4:
11
.
(25 February 2026)
Editorial Commentary
Chimeric antigen receptor T cell therapy in prostate cancer: racing to prime time
AME Clinical Trials Review
2026;
4:
10
.
(25 February 2026)
Editorial Commentary
Long-term clopidogrel for secondary prevention—towards resolution of complex problem?
AME Clinical Trials Review
2026;
4:
9
.
(25 February 2026)
Editorial Commentary
Encorafenib, cetuximab and chemotherapy: a mole against BRAF mutant metastatic colorectal cancer
AME Clinical Trials Review
2026;
4:
8
.
(25 February 2026)
Editorial Commentary
Ibrutinib’s role in early-stage chronic lymphocytic leukemia: delayed progression but no survival advantage
AME Clinical Trials Review
2026;
4:
7
.
(25 February 2026)
Editorial Commentary
Asciminib: a revolution in the tyrosine kinase inhibitors era
AME Clinical Trials Review
2026;
4:
6
.
(25 February 2026)
Editorial Commentary
The role of lisocabtagene maraleucel for relapsed/refractory follicular lymphoma: a commentary
AME Clinical Trials Review
2026;
4:
5
.
(25 February 2026)
Review Article
From the PACIFIC to the ADRIATIC: a literature review of 38 years of failed maintenance trials in small cell lung cancer post-chemoradiation
AME Clinical Trials Review
2026;
4:
4
.
(25 February 2026)
Review Article
Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer: a narrative review
AME Clinical Trials Review
2026;
4:
3
.
(25 February 2026)
Review Article
The role of minimal residual disease measurement in multiple myeloma
AME Clinical Trials Review
2026;
4:
2
.
(25 February 2026)
Review Article
First-line treatment strategies and potential prognostic factors in patients with KRAS G12C-mutant non-small cell lung cancer
AME Clinical Trials Review
2026;
4:
1
.
(25 February 2026)